KIN - Kindred Biosciences, Inc.

Kindred Biosciences, Inc.

1555 Bayshore Highway
Suite 200
Burlingame, CA 94010
United States
650-701-7901
http://www.kindredbio.com

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 146

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Richard Chin	Co-Founder, CEO & Director	743.6k	N/A	1967
Ms. Denise M. Bevers	Co-Founder, Pres, COO, Sec. & Director	590.56k	N/A	1967
Ms. Wendy K. Wee	Chief Financial Officer	414.5k	N/A	1953
Dr. Hangjun Zhan	Chief Scientific Officer	419.1k	N/A	1960
Ms. Katja Buhrer	VP of Corp. Devel. & Investor Relations	N/A	N/A	N/A

Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-014 to treat gastric ulcers in horses; epoCat, a feline recombinant erythropoietin for the management of anemia in cats; KIND-011, a monoclonal antibody that targets sick or septic foals; and KIND-509, an antibody for canine inflammatory bowel disease. Further, it is developing KIND-015 for the management of clinical signs associated with equine metabolic syndrome and anti-tumor necrosis factor in septic foals; KIND-502, an IgE antibody that targets the canine counterpart of the human target for allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; and various antibodies that target cytokines involved in atopic dermatitis, as well as interleukin antibodies and canine checkpoint inhibitors. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.

Corporate Governance

Kindred Biosciences, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.